


PRODUCT INFORMATION



Remoxipride (hydrochloride)

Item No. 30971

CAS Registry No.: 73220-03-8
Formal Name: 3-bromo-N-[[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxy-benzamide, monohydrochloride
MF: C₁₆H₂₃BrN₂O₃ • HCl
FW: 407.7
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Remoxipride (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the remoxipride (hydrochloride) in water. The solubility of remoxipride (hydrochloride) in water is approximately 100 nM. We do not recommend storing the aqueous solution for more than one day.

Description

Remoxipride is an atypical antipsychotic and dopamine D₂ receptor antagonist (K_i = 0.2 μM).¹ It is selective for the dopamine D₂ receptor over a panel of 33 receptors, neurotransmitter transporters, and ion channels at 10 μM but does inhibit the sigma (σ) receptor (K_i = 0.065 μM). Remoxipride (2-20 μmol/kg, i.p.) increases striatal 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels in rats.² It inhibits apomorphine-induced stereotypy and hyperactivity in rats with ED₅₀ values of 5.6 and 0.8 μmol/kg, respectively.³ Formulations containing remoxipride have previously been used in the treatment of schizophrenia.

References

1. Leysen, J.E., Janssen, P.M.F., Schotte, A., *et al.* Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT₂ receptors. *Psychopharmacology (Berl)*. **112(1 Suppl.)**, S40-54 (1993).
2. Magnusson, O., Mohringe, B., Thorell, G., *et al.* Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration. *Pharmacol. Toxicol.* **60(5)**, 368-373 (1987).
3. Ogren, S.O., Hall, H., Kohler, C., *et al.* Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. *Eur. J. Pharmacol.* **102(3-4)**, 459-574 (1984).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM